A Simplified PET/CT Measurement Routine with Excellent Diagnostic Accuracy for the Diagnosis of Giant Cell Arteritis.
PET/CT
SUV
diagnosis
giant cell arteritis
imaging
large-vessel-vasculitis
validation
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
17 Mar 2022
17 Mar 2022
Historique:
received:
06
02
2022
revised:
14
03
2022
accepted:
15
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
We previously proposed standard uptake value (SUV) ratio-based cut-off values for [18F] fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) for diagnosing giant cell arteritis (GCA) with high diagnostic accuracy. Here we confirm our findings in an independent cohort and report a simplified procedure for using a SUV ratio to diagnose LV-GCA. Patients with suspected GCA were consecutively included. The ‘peak SUV ratio’ was defined in a two-step approach. First, the vessel with the visually brightest radiotracer uptake in the supra-aortic (SA) and in the aorto-iliofemoral (AIF) region was identified. Here, the maximum SUV of the vessel was measured and divided by the mean SUV of the liver (SUVratio). A ratio >1.0 in the SA or >1.3 in the AIF region was scored as vasculitis. The diagnostic accuracy, sensitivity, and specificity of the ‘peak SUV ratio’ in the SA and AIF region was assessed. From 2015 to 2019, 50 patients (24 female, median age 71 years) with suspicion of GCA were included, 28 patients with GCA and 22 patients with exclusion of GCA. Peak SUV had an AUC of 0.91, a sensitivity of 0.89, and a specificity of 0.73 for diagnosing GCA. Peak SUV accuracy of the AIF arteries was lower (AUC 0.81) than of the SA arteries (AUC 0.95). Our SUV ratio cut-off values for diagnosing GCA are consistently valid, also when applied in a time-efficient clinical procedure focusing on the peak SUV ratio. The diagnostic performance of PET/CT in this validation cohort was even higher, compared to the inception cohort (AUC of 0.83).
Identifiants
pubmed: 35328281
pii: diagnostics12030728
doi: 10.3390/diagnostics12030728
pmc: PMC8946981
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swiss National Science Foundation
ID : 310030_192440
Pays : Switzerland
Organisme : Schweizerische Stiftung für die Forschung der Muskelkrankheiten
Références
Clin Nucl Med. 2001 Apr;26(4):314-9
pubmed: 11290891
Ann Rheum Dis. 2010 Jul;69(7):1356-9
pubmed: 20498213
Swiss Med Wkly. 2018 Aug 22;148:w14661
pubmed: 30141518
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
Am J Med. 2000 Feb 15;108(3):246-9
pubmed: 10723979
Diagnostics (Basel). 2021 Dec 14;11(12):
pubmed: 34943593
Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):933-940
pubmed: 29126277
Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):674-81
pubmed: 15747154
Medicine (Baltimore). 2015 Sep;94(37):e1542
pubmed: 26376404
Ann Rheum Dis. 2018 May;77(5):636-643
pubmed: 29358285
Eur J Nucl Med Mol Imaging. 2003 May;30(5):730-6
pubmed: 12677302
Arthritis Rheum. 1990 Aug;33(8):1122-8
pubmed: 2202311
J Nucl Med. 2008 Jul;49(7):1107-13
pubmed: 18552151
Biomed Res Int. 2014;2014:574248
pubmed: 25254211